Primo Lara

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients
    Mark Levandovsky
    Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, CA, USA
    J Hematol Oncol 1:23. 2008
  2. ncbi Malignant thymoma: current status and future directions
    P N Lara
    Division of Hematology Oncology, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA, 95817, USA
    Cancer Treat Rev 26:127-31. 2000
  3. ncbi Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study
    Primo N Lara
    California Cancer Consortium at the University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4356-62. 2003
  4. ncbi Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817-2229, USA
    Clin Lung Cancer 7:353-6. 2006
  5. ncbi A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases
    Primo N Lara
    University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
    Clin Cancer Res 12:1556-63. 2006
  6. ncbi Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 23:9282-9. 2005
  7. ncbi Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma
    Primo N Lara
    Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 100:82-8. 2004
  8. ncbi Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S67-71. 2005
  9. ncbi A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Anticancer Drugs 20:179-84. 2009
  10. ncbi Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 27:2530-5. 2009

Research Grants

  1. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo Lara; Fiscal Year: 2007
  2. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo Lara; Fiscal Year: 2009
  3. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo N Lara; Fiscal Year: 2010

Detail Information

Publications89

  1. ncbi Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients
    Mark Levandovsky
    Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, CA, USA
    J Hematol Oncol 1:23. 2008
    ..We performed a retrospective cohort study of 178 consecutively treated patients with TTP-HUS and analyzed whether clinical or laboratory characteristics could predict for important short- and long-term outcome measures...
  2. ncbi Malignant thymoma: current status and future directions
    P N Lara
    Division of Hematology Oncology, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA, 95817, USA
    Cancer Treat Rev 26:127-31. 2000
    ..Multicentre co-operative group clinical trials are required to assess novel thymoma therapies to maximize patient resources in this uncommon tumour...
  3. ncbi Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study
    Primo N Lara
    California Cancer Consortium at the University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4356-62. 2003
    ..We conducted a Phase I study of tirapazamine, carboplatin, and paclitaxel and assessed potential plasma markers of hypoxia as surrogates for response...
  4. ncbi Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817-2229, USA
    Clin Lung Cancer 7:353-6. 2006
  5. ncbi A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases
    Primo N Lara
    University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
    Clin Cancer Res 12:1556-63. 2006
    ..Serial serum and urine specimens were collected to assess for markers of bone metabolism...
  6. ncbi Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 23:9282-9. 2005
    ..We evaluated the level of awareness of patients and/or their family members/friends regarding CCTs and SB37...
  7. ncbi Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma
    Primo N Lara
    Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 100:82-8. 2004
    ..However, the toxicities of platinum-based chemotherapy are considerable. Regimens with reduced toxicity that are applicable to a broader group of TCC patients without sacrificing activity therefore are of interest...
  8. ncbi Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S67-71. 2005
    ..Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Efforts to promote apoptosis in SCLC through the integration of bortezomib into therapy are under way...
  9. ncbi A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Anticancer Drugs 20:179-84. 2009
    ..Strong preclinical evidence warrants further investigation of AZD0530 in earlier-stage prostate cancer or as combination therapy...
  10. ncbi Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 27:2530-5. 2009
    ..To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large randomized trial of identical design to the Japanese trial in North American patients with E-SCLC...
  11. ncbi Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 100:2125-31. 2004
    ..The authors screened for HER-2 overexpression in patients developing hormone-refractory prostate carcinoma (HRPC) and conducted a Phase II trial of trastuzumab plus docetaxel in HER-2-positive patients...
  12. ncbi Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 6:102-7. 2004
    ..06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC...
  13. ncbi Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Anticancer Drugs 16:317-21. 2005
    ..Three of these prolonged stable disease patients had non-small cell lung cancer. We conclude that intermittent dosing of R115777 is feasible and tolerable. The recommended phase II dose is 600 mg orally b.i.d. on alternate weeks...
  14. ncbi Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
    Primo N Lara
    University of California, Davis Cancer Center, 4501 X St, Suite 3016, Sacramento, CA, USA
    J Clin Oncol 29:2965-71. 2011
    ....
  15. ncbi Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 116:5710-5. 2010
    ..Because 0124 and 9511 used identical treatment regimens and similar eligibility criteria, patient-level data were pooled from both trials, and a common arm analysis was performed to explore potential reasons for the divergent results...
  16. ncbi Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment
    P N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 19:1728-33. 2001
    ..Unfortunately, only 3% of new cancer patients participate in clinical trials. Barriers to patient accrual in cancer clinical trials must be identified and overcome to increase patient participation...
  17. ncbi Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
    P N Lara
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento 95817, USA
    Cancer Chemother Pharmacol 48:22-8. 2001
    ..In view of these findings, we hypothesized that toremifene would reverse platinum resistance and that this interaction would be influenced by tumor estrogen receptor (ER) status...
  18. ncbi Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials
    Primo N Lara
    University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA
    J Clin Oncol 26:463-7. 2008
    ....
  19. ncbi Non-small-cell lung cancer progression after first-line chemotherapy
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Curr Treat Options Oncol 3:53-8. 2002
    ..In view of the recently established role of docetaxel, ongoing randomized studies are using a common design of single-agent docetaxel versus docetaxel plus a novel investigational agent...
  20. ncbi Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    J Thorac Oncol 1:996-1001. 2006
    ..We conducted a phase II trial of PS-341 in previously treated patients with platinum-sensitive and -refractory extensive stage SCLC to determine response rate, toxicity, and survival...
  21. ncbi HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial
    Primo N Lara
    University of California Davis Cancer Center, Division of Hematology Oncology, 4501 X Street, Sacramento, CA 95817, USA
    Cancer 94:2584-9. 2002
    ..The authors report the results of HER-2 screening from a Phase II trial of chemotherapy with trastuzumab and docetaxel in patients with HER-2-overexpressing prostate carcinoma...
  22. ncbi The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 11:4444-50. 2005
    ..Our group has previously shown that UCN-01 potentiates the apoptotic response of agents such as cisplatin in vitro by preventing sequence-specific abrogation of G2 arrest caused by DNA-damaging chemotherapies...
  23. ncbi Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 12:33-7. 2011
    ..A prospective randomized phase II trial of concurrent versus sequential docetaxel and bortezomib was conducted to assess whether administration sequence resulted in measurable clinical differences...
  24. ncbi Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 1:126-34. 2006
    ..This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors...
  25. ncbi Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 5:231-6. 2004
    ..In view of the limited target population for HER2 inhibition, future efforts and resources should be directed toward molecular targets other than HER2 in NSCLC...
  26. ncbi Angiogenesis-targeted therapies in prostate cancer
    Primo N Lara
    University of California Davis Cancer Center, 4501 X St, Suite 3016, Sacramento, CA 95817, USA
    Clin Prostate Cancer 3:165-73. 2004
    ..This review summarizes the molecular mechanisms implicating angiogenesis in the development and progression of advanced-stage prostate cancer, as well as the drug development efforts that are targeting this process...
  27. ncbi Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)
    Angela M Davies
    Department of Hematology Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:87-92. 2009
    ..This phase II study of bortezomib in combination with gemcitabine/carboplatin was conducted in chemotherapy-naive advanced NSCLC patients to assess efficacy and safety...
  28. ncbi Population-based phase I trial of irinotecan and epirubicin
    Derick Lau
    Department of Internal Medicine, University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Am J Clin Oncol 31:226-30. 2008
    ..A population-based phase I trial was conducted to determine a population-based maximum tolerated dose (pMTD) for combining 2 topoisomerase inhibitors, irinotecan and epirubicin...
  29. ncbi Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, USA
    J Clin Oncol 21:2004-10. 2003
    ..Nevertheless, this study remains hypothesis-generating and does not provide definitive evidence of the benefit of this approach. Phase III trials evaluating the S9504 regimen have been initiated to validate these results...
  30. ncbi Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial
    Przemyslaw Twardowski
    City of Hope Cancer Ctr, Duarte, CA, USA
    Urology 76:923-6. 2010
    ..Evidence has shown that vascular endothelial growth factor is important in the pathophysiology of urothelial cancer...
  31. ncbi Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer
    Melinda M Mortenson
    Division of Surgical Oncology, Suite 3010, University of California, Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Lung Cancer 49:163-70. 2005
    ..These data provide the necessary laboratory background for further investigation of bortezomib in the treatment of SCLC...
  32. ncbi Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
    Philip C Mack
    Cancer and Molecular Research Laboratory, Division of Hematology/Oncology, Department of Internal Medicine, University of California, Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Cancer Chemother Pharmacol 51:337-48. 2003
    ..These findings support the hypothesis that checkpoint abrogation is the major mechanism of UCN-01-mediated potentiation of cisplatin cytotoxicity...
  33. ncbi Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222
    Quynh Thu X Le
    Stanford University, Stanford, CA, USA
    J Clin Oncol 27:3014-9. 2009
    ..We report results of the phase II study designed to confirm this result...
  34. ncbi Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003
    Stephen K Williamson
    University of Kansas Medical Center, Kansas City, KS, USA
    J Clin Oncol 23:9097-104. 2005
    ..003). CONCLUSION: The addition of tirapazamine to paclitaxel and carboplatin does not result in improved survival in advanced NSCLC compared with paclitaxel and carboplatin alone but substantially increases toxicity...
  35. ncbi Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer
    Angela Davies
    Division of Hematology/Oncology, University of California Davis Cancer Center, Sacramento, CA 95817-2229, USA
    Semin Oncol 29:10-6. 2002
    ....
  36. ncbi Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:862-8. 2009
    ..Pharmacodynamic separation by intermittent delivery of epidermal growth factor receptor tyrosine kinase inhibitors with chemotherapy may increase efficacy by overcoming hypothesized antagonism...
  37. ncbi SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4772-81. 2003
    ..Efficacy was correlated with serial plasma VEGF and plasminogen activator inhibitor-1 levels and with positron emission tomography scans...
  38. ncbi Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949
    Primo N Lara
    University of California at Davis, Sacramento, California, USA
    J Urol 181:512-6; discussion 516-7. 2009
    ..We present an updated analysis of S8949, now with a median followup of 9 years. We explored clinical predictors of overall survival...
  39. ncbi Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:247-56. 2007
    ..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome...
  40. ncbi Premedication strategy for weekly paclitaxel
    Justin Quock
    University of California, Davis Cancer Center, VA Northern California Health Care System, 4501 X Street, Sacramento, CA 95817, USA
    Cancer Invest 20:666-72. 2002
    ..CONCLUSION: We conclude that this premedication strategy is feasible and worthy of further study for patients receiving weekly paclitaxel...
  41. ncbi Population-based maximum tolerated dose of irinotecan and carboplatin
    Carolyn A Wild
    University of California, Davis Cancer Center, Veterans Administration, Northern California Health Care System, Sacramento, California, USA
    Oncology (Williston Park) 17:11-6. 2003
    ..We recommend dose level 1 of irinotecan (200 mg/m2) and carboplatin (AUC 5) for chemotherapynaive patients, and dose level-1 of irinotecan (150 mg/m2) and carboplatin (AUC 5) for chemotherapy-treated patients in phase II trials...
  42. ncbi Phase I trial of gemcitabine and paclitaxel in advanced solid tumors
    Nelson Lim
    Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis School of Medicine, Sacramento, California, USA
    Cancer Invest 21:7-13. 2003
    ..The recommended phase II dose is gemcitabine 1000 mg/m2 and paclitaxel 150 mg/m2 on days one and eight every 21 days. The antitumor activity observed with this regimen warrants further investigation...
  43. ncbi Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
    Maha Hussain
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:8724-9. 2005
    ..The epothilones are a new class of tubulin-polymerizing agents with activity in taxane-sensitive and resistant tumor models. We evaluated ixabepilone (BMS-247550) in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  44. ncbi Is the use of anything but MVAC justified in the evidence-based medicine era?
    Joon Ha Ok
    Curr Opin Urol 15:312-4. 2005
  45. ncbi Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
    Maha H A Hussain
    University of Michigan, Ann Arbor, USA
    J Clin Oncol 25:2218-24. 2007
    ....
  46. ncbi Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Daniel P Petrylak
    Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
    N Engl J Med 351:1513-20. 2004
    ....
  47. ncbi Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    Daniel P Petrylak
    Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 98:516-21. 2006
    ..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial...
  48. ncbi Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer
    Gigi Chen
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 27:1401-4. 2009
    ..We conducted a multi-institution phase II trial to evaluate a novel 21-day schedule of irinotecan and carboplatin in patients with relapsed or extensive SCLC...
  49. ncbi The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
    Phillip R Purnell
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:448-54. 2009
    ..This will facilitate the development of tests to identify patients who may benefit from these agents, allow drug activity to be monitored and rationalize the combination of these agents with other treatment modalities...
  50. ncbi Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy
    Primo N Lara
    Department of Internal Medicine, University of California Davis School of Medicine, UCD Cancer Center, Sacramento 95817, USA
    Semin Oncol 31:40-6. 2004
    ..PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer...
  51. ncbi Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia
    David R Gandara
    Division of Hematology-Oncology and the Department of Radiation Oncology, University of California, Sacramento, CA 95817, USA
    Semin Oncol 29:102-9. 2002
    ..This article reviews the preclinical and clinical development of tirapazamine, as well as current trials in non-small cell lung cancer designed to provide proof of principle for this new category of cancer therapeutics...
  52. ncbi Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone
    Donna L Berry
    University of Washington, Seattle, WA 98195 7266, USA
    J Clin Oncol 24:2828-35. 2006
    ..While Southwest Oncology Group trial 99-16 demonstrated a survival improvement of DE over MP, the study also was designed to compare the palliation of disease-related symptoms...
  53. ncbi Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer
    James R Rigas
    Dartmouth Medical School, 1 Medical Center Drive, Lebanon, NH 03756, USA
    Lung Cancer 50:S17-24. 2005
    ..A randomized trial is currently underway that compares concurrent chemoradiotherapy (using cisplatin and etoposide) followed by either docetaxel consolidation or no further therapy...
  54. ncbi EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer
    Philip C Mack
    Division of Hematology and Oncology, University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 4:1466-72. 2009
    ..We hypothesized that analysis of plasma for EGFR and KRAS mutations from shed tumor DNA would have clinical utility...
  55. ncbi Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation
    Christopher M Mahaffey
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:548-53. 2007
    ..We hypothesized that the lack of benefit resulted from a negative interaction between chemotherapy and EGFR TKIs...
  56. ncbi Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics
    David R Gandara
    University of California Davis Cancer Center, 4501 X St, Suite 3017, Sacramento, CA 95817 2229, USA
    J Clin Oncol 27:3540-6. 2009
    ..This common-arm approach facilitates the prospective study of population-related pharmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated...
  57. ncbi A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)
    Ralph W deVere White
    University of California at Davis, Sacramento, California 95817, USA
    J Urol 181:2476-80; discussion 2480-1. 2009
    ....
  58. ncbi Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier
    Randeep Sangha
    University of California, Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Curr Opin Oncol 21:116-23. 2009
    ..Several lines of evidence suggest that these novel approaches may play a relevant role in the future treatment of NSCLC...
  59. ncbi Cooperative group research endeavors in small-cell lung cancer: current and future directions
    Randeep Sangha
    Division of Hematology Oncology, University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 10:322-30. 2009
    ..Continued research efforts sponsored by these groups will represent the future of SCLC diagnosis and management...
  60. ncbi Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer
    David R Gandara
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 5:1933-8. 2010
    ..We investigated the relationship of EGFR mutation status and DNA repair capacity, as exemplified by excision repair cross-complementing 1 (ERCC1) gene expression, as a potential explanation for this observation...
  61. ncbi Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer
    Tianhong Li
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Curr Drug Targets 11:85-94. 2010
    ..Ongoing research efforts investigating this concept are reviewed...
  62. ncbi The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study
    Angela M Davies
    Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA
    J Thorac Oncol 3:68-74. 2008
    ..The combination of gemcitabine and carboplatin is an accepted first-line treatment for advanced NSCLC. We conducted a phase I study of gemcitabine and carboplatin in combination with bortezomib...
  63. ncbi Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
    Angela M Davies
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:1112-6. 2007
    ..We examined the safety and tolerability of pemetrexed in combination with two different schedules of bortezomib in patients with advanced solid tumors...
  64. ncbi Asian Americans and cancer clinical trials: a mixed-methods approach to understanding awareness and experience
    Debora A Paterniti
    Center for Health Services Research in Primary Care, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Cancer 104:3015-24. 2005
    ....
  65. ncbi High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
    Carol M Richman
    University of California Davis, Sacramento, California 95817, USA
    Clin Cancer Res 11:5920-7. 2005
    ..In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced breast cancer...
  66. ncbi Recent developments in advanced urothelial cancer
    Karen Giselle Chee
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Curr Opin Urol 15:342-9. 2005
    ..The long-term survival data and the associated toxicities from this form of therapy have spurred continuing interest in finding novel treatment options for this malignancy...
  67. ncbi Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer
    David Gandara
    Department of Internal Medicine, Division of Hematology Oncology and Department of Radiation Oncology, UC Davis Cancer Center, University of California Davis Medical Center, 4501 X Street, Sacramento, CA 95817, USA
    Clin Cancer Res 11:5057s-5062s. 2005
    ..Here, we describe conceptual issues, preclinical rationale, and ongoing or planned clinical trials incorporating NTAs into current treatment paradigms for unresectable stage III NSCLC...
  68. ncbi Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved
    Peter F Roberts
    Division of Cardiothoracic Surgery, University California, Davis Medical Center, Sacramento, 95817, USA
    J Thorac Cardiovasc Surg 126:1597-602. 2003
    ..The staging and treatment of multifocal non-small cell cancer are controversial. We evaluated the current staging of multifocal bronchioloalveolar carcinoma and the therapeutic effectiveness of resection when this tumor type is involved...
  69. ncbi Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for
    Sally J DeNardo
    University of California Davis School of Medicine, Sacramento, California 95816, USA
    Clin Cancer Res 9:3938S-44S. 2003
    ....
  70. ncbi Docetaxel in non-small cell lung cancer: a review
    Angela M Davies
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Expert Opin Pharmacother 4:553-65. 2003
    ..This paper will review the pharmacology, preclinical, clinical and pharmacoeconomic data supporting the use of docetaxel in the treatment NSCLC...
  71. ncbi Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Regina Gandour-Edwards
    Department of Pathology, School of Medicine, University of California Davis, 95817, USA
    Cancer 95:1009-15. 2002
    ..Thus, the authors evaluated a possible correlation between HER2 expression in patients with high-grade, muscle-invasive urothelial carcinoma of the bladder and outcome in patients who received paclitaxel-based chemotherapy...
  72. ncbi Bortezomib-based combinations in the treatment of non-small-cell lung cancer
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S59-63. 2005
    ..This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date...
  73. ncbi Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy
    David R Gandara
    Department of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Clin Lung Cancer 7:S93-7. 2005
    ..Herein, we review the rationale for a treatment paradigm employing consolidation docetaxel therapy after concurrent chemotherapy/RT and the results of recent clinical trials using this approach...
  74. ncbi Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007
    ....
  75. ncbi Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Invest New Drugs 25:351-5. 2007
    ....
  76. ncbi Small-cell carcinoma of the urinary bladder: diagnosis and management
    Chong Xian Pan
    University of California at Davis, Department of Internal Medicine, Division of Hematology Oncology, Department of Urology, 4501 X Street, Room 3016, Sacramento, CA 95817, USA
    Expert Rev Anticancer Ther 6:1707-13. 2006
    ..This article provides a comprehensive review of the current status of SCCUB diagnosis and management, as well as some unique insights into this rare tumor...
  77. ncbi Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:116-21. 2006
    ..Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation...
  78. ncbi Aurora kinase inhibitors: a new class of targeted drugs in cancer
    Oliver Gautschi
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:93-8. 2006
    ..This article reviews the biology of aurora kinases, their potential role in the treatment of lung cancer, and challenges in the clinical development of this unique class of antineoplastic agents...
  79. ncbi Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
    Angela M Davies
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:385-8. 2006
    ..Herein we provide the preclinical and clinical rationale for studies examining the concept of pharmacodynamic separation as a means for overcoming hypothesized antagonism of EGFR TKIs and chemotherapy...
  80. ncbi Predictive molecular markers: has the time come for routine use in lung cancer?
    Angela M Davies
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California, USA
    J Natl Compr Canc Netw 2:125-31. 2004
    ..To date, none of these markers can be recommended for routine use in clinical practice...
  81. ncbi Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003
    Philip C Mack
    Division of Hematology and Oncology, University of California, Davis Cancer Center, 4501 X St, Ste 3016, Sacramento, CA 95817, USA
    J Clin Oncol 26:4771-6. 2008
    ..We investigated the relationship between clinical outcomes and plasma levels of the hypoxia-associated protein osteopontin (OPN) in patients on this protocol...
  82. ncbi Incorporating bortezomib into the treatment of lung cancer
    Angela M Davies
    UC Davis Cancer Center, University of California, Sacramento, California 95817, USA
    Clin Cancer Res 13:s4647-51. 2007
    ..Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma...
  83. ncbi Treatment of extensive small cell lung cancer
    Angela M Davies
    University of California-Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Hematol Oncol Clin North Am 18:373-85. 2004
  84. ncbi Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Philip C Mack
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Lung Cancer 41:S89-96. 2003
    ..PS-341 is currently in phase I/II clinical development in lung cancer. This paper will review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer...
  85. ncbi Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?
    Primo N Lara
    Clin Lung Cancer 7:232-4. 2006
  86. ncbi Adjuvant therapy in completely resected malignant thymoma
    Primo N Lara
    Cancer Invest 21:815-6. 2003
  87. ncbi Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results
    Primo N Lara
    Clin Lung Cancer 9:141-3. 2008
  88. ncbi Current strategies in the management of hormone refractory prostate cancer
    Cynthia L Martel
    Division of Hematology and Oncology, University of California, Davis, Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Cancer Treat Rev 29:171-87. 2003
    ....
  89. ncbi An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California
    Cynthia L Martel
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer J 10:294-300. 2004
    ..Efforts to increase participation must include enhancing physician and patient awareness of SB37...

Research Grants6

  1. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo Lara; Fiscal Year: 2007
    ....
  2. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo Lara; Fiscal Year: 2009
    ....
  3. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo N Lara; Fiscal Year: 2010
    ....